Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial
KEYWORDS: warfarin, rivaroxaban, manufacturer, committee, erg, population, people, risk, model, trial, stroke, treatment, noted, analysis, etexilate

Committee discussed the disutility values used in the manufacturer's updated economic analyses. It noted that the manufacturer had used a small study of 57 patients to justify including a disutility associated with warfarin. The Committee acknowledged that comments received during consultation implied that warfarin was associated with disadvantages. However, the Committee was mindful that the manufacturer had assumed that there was no disutility associated with rivaroxaban and had not provided any rationale for its exclusion. The Committee noted the comments from the ERG and consultees and commentators suggesting that there could be some disutility associated with newer anticoagulation therapy, including concerns about non-reversibility in the case of bleeding. However, the Committee noted that no specific evidence relating to disutility associated with anticoagulation therapy other than warfarin had been submitted by any consultees and commentators or by the ERG. The Committee therefore agreed that although it was appropriate to consider that there might be a disutility associated with warfarin treatment, it was not appropriate to assume that there was no disutility associated with rivaroxaban and other anticoagulant treatments. The Committee concluded that the disutility value used in the economic model for warfarin may have resulted in a bias in the manufacturer's
